Cancer Discovery

Cancer Discovery is a premier peer-reviewed journal published by the American Association for Cancer Research (AACR), dedicated to publishing major advances in cancer research that have high clinical and translational impact. With an ISSN of 2159-8274 and an abbreviation of CANCER DISCOV, the journal focuses on a broad scope encompassing original, high-impact research articles that reveal novel biological insights into cancer initiation, progression, and therapy resistance. Its primary topics include tumor microenvironment interactions, genomic alterations, immunotherapy mechanisms, drug discovery and development, precision oncology, and biomarker validation. The journal features a curated selection of article types, including original research articles, brief reports, reviews, perspectives, and commentary pieces that highlight emerging concepts and critical clinical challenges. The target audience comprises academic researchers, clinical oncologists, pharmacologists, and translational scientists seeking cutting-edge findings that bridge laboratory discoveries and patient care. Cancer Discovery is distinguished by its exceptionally high impact factor of 29.5000 for 2026, placing it in the JCR Quartile 1 (Q1) within oncology and related disciplines, thereby ranking among the most influential journals in the field. Notable features include a rigorous, selective peer-review process, optional open access options, and the journal’s commitment to accelerating the translation of basic science into clinical applications. As a flagship AACR title, Cancer Discovery is widely regarded as an authoritative source for paradigm-shifting discoveries that define the future of cancer diagnosis, treatment, and prevention.